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Objective: Elevated uric acid levels have been associated with an adverse cardiovascular outcome in several set-
tings. Their utility in patients undergoing surgical revascularization has not, however, been assessed. We hypoth-
esized that serum uric acid levels would predict the outcome of patients undergoing coronary artery bypass
grafting.
Methods: The study cohort consisted of 1140 consecutive patients undergoing nonemergency coronary artery
bypass grafting. Clinical details were obtained prospectively, and serum uric acid was measured a median of 1
day before surgery. The primary end point was all-cause mortality.
Results: During a median of 4.5 years, 126 patients (11%) died. Mean ( standard deviation) uric acid levels
were 390  131 mmol/L in patients who died versus 353  86 mmol/L among survivors (hazard ratio 1.48 per
100 mmol/L; 95% confidence interval, 1.25–1.74; P< .001). The excess risk associated with an elevated uric
acid was particularly evident among patients in the upper quartile (410 mmol/L; hazard ratio vs all other quar-
tiles combined 2.18; 95% confidence interval, 1.53–3.11; P<.001). After adjusting for other potential prognostic
variables, including the European System for Cardiac Operative Risk Evaluation, uric acid remained predictive of
outcome.
Conclusion: Increasing levels of uric acid are associated with poorer survival after coronary artery bypass graft-
ing. Their prognostic utility is independent of other recognized risk factors, including the European System for
Cardiac Operative Risk Evaluation.See related editorial on page 8.
Uric acid is produced by purine metabolism. Higher levels
are found in patients with vascular disease and in those
with major cardiovascular risk factors, such as hypertension,
diabetes mellitus, obesity, hyperinsulinemia/insulin resis-
tance, and renal dysfunction.1-3 Hyperuricemia is also asso-
ciated with multiple biological effects, several of which are
detrimental to cardiovascular health. These include oxida-
tive stress, generation of free radicals, impaired endothelial
function, increased platelet adhesiveness, and higher levels
of inflammatory markers.1,4-8
Many, although not all, epidemiologic studies have sug-
gested that high levels are independently predictive of
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In patients who are at high risk of or who have established
vascular disease, an independent association has been
more clearly established.3,12-19 The relationship between
uric acid levels and the outcome from surgical revasculariza-
tion has not, however, been previously examined. Given the
relationship between uric acid and other major risk factors,
the effects of hyperuricemia on platelet and endothelial func-
tion, the putative role of products of purine breakdown in
reperfusion injury, and the prognostic utility of increased
levels in other settings, we hypothesized that elevated uric
acid levels would predict a worse outcome from coronary
artery bypass grafting (CABG). The current study tests
this hypothesis.
MATERIALS AND METHODS
Ethical approval for the study was granted by the local research ethics
committee. Between April 2000 and September 2002, 1221 consecutive pa-
tients underwent CABG at Aberdeen Royal Infirmary. Patients who under-
went emergency surgery or surgery within 1 week of an acute myocardial
infarction (n ¼ 61) were excluded, as were 20 subjects who had no preop-
erative uric acid measurement. The study cohort consisted of the remaining
1140 patients.
Baseline clinical data, including medical history, cardiac risk factors, op-
erative details, New York Heart Association functional class, and the Euro-
pean System for Cardiac Operative Risk Evaluation (EuroSCORE),20 were
collected prospectively by an experienced full-time data collector. Serum
samples were collected a median of 1 day (interquartile range 1–2 days)
preoperatively, and uric acid measured using the ADVIA 1650 Generalgery c July 2009
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CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
EuroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
HR ¼ hazard ratio
Chemistry Analyzer (Siemens Diagnostics Solutions, Tarrytown, NY).
Hyperuricemia was defined as  416 mmol/L (7.0 mg/dL) in men and 
357 mmol/L (6.0 mg/dL) in women.21,22 Renal function was measured,
and the glomerular filtration rate was estimated from the Modification of
Diet in Renal Disease equation.23
Follow-up
Patients were followed up using computerized hospital records and a vital
events search performed by the General Register Office for Scotland. The
primary end point was all-cause mortality. Secondary end points were a)
cardiovascular mortality, b) all-cause mortality in patients undergoing iso-
lated CABG, c) all-cause 30-day mortality, and d) late (>30 days) mortality.
Cause of death was defined as cardiovascular if this was listed on the death
certificate as the primary cause or a contributory factor.
Statistics
Categoric data are expressed as number (%) and continuous variables as
mean (standard deviation) if normally distributed or median (interquartile
range) if skewed. The influence of potential risk factors was explored using
Cox regression, and hazard ratios (HRs) are presented with 95% confidence
intervals (CIs). An a priori decision to include risk factors in multiple Cox
regression models was based on univariate P values less than .25 or an es-
timated univariate HR greater than 2. Model fit was assessed using the log-
likelihood and inspecting residuals. Models are presented and discussed for
uric acid as a continuous variable, in quartiles, and as a dichotomous
variable (‘‘hyperuricemia’’). Comparisons of baseline characteristics
among patients with uric acid levels in differing quartiles were made using
the chi-square test and analysis of variance as appropriate. Binary logistic
regression was used for 30-day mortality, and odds ratios plus 95% CI
are presented. Statistical analyses were performed using SPSS version
15.0 for Windows (SPSS, Chicago, IL).
RESULTS
The study cohort was predominantly male with a median
age of 66 years (Table 1). A total of 1023 patients underwent
isolated CABG, with 59 patients having 1 vessel grafted,
342 patients having 2 vessels grafted, 522 patients having
3 vessels grafted, and 100 patients having more than 3 ves-
sels grafted. The remaining 117 patients had more complex
procedures in addition to CABG. These included 107 valve
replacements/repairs (80 aortic valve replacements, 26 mi-
tral valve replacements/repairs, and 1 combined aortic and
mitral valve operation). The remaining 10 complex proce-
dures consisted of CABG in combination with left ventricu-
lar aneurysmectomy (n ¼ 6), myxoma resection (n ¼ 2),
aortic root surgery (n ¼ 1), and pericardiectomy (n ¼ 1).
In 1038 patients, surgery was performed using cardiopulmo-
nary bypass. The remaining 102 patients underwent ‘‘off-
pump’’ surgery.The Journal of Thoracic andThe mean uric acid level was 357 92 mmol/L (6.0 1.5
mg/dL). Hyperuricemia was present in 284 subjects (25%).
Vital status was available for all patients. During a median of
4.5 (3.8–5.2) years, 126 patients (11%) died (primarily or
partly from cardiovascular causes in 107).
Univariable Predictors of All-Cause Mortality
Serum uric acid was a univariable predictor of mortality
(Table 1). Other univariable predictors included age, im-
paired left ventricular systolic function, requirement for
a major cardiac procedure in addition to CABG, bypass or
crossclamp time, renal function, and the EuroSCORE.
Multivariable Predictors of All-Cause Mortality
All prognostic variables in Table 1 were considered for in-
clusion in a multiple Cox regression model, except the Euro-
SCORE (which is a composite that includes several of these
parameters) and crossclamp time (which is closely related to,
but inferior in terms of prognostic utility to, bypass time). In
the most parsimonious regression model, uric acid levels
remained independently predictive (Table 2). In a further
model, including uric acid and the EuroSCORE only, both
were independent predictors of mortality (HR for Euro-
SCORE 1.33 per unit increase; 95% CI, 1.25–1.42; P<
.001; HR for uric acid 1.32 per 100 mmol/L; 95% CI,
1.13–1.54; P ¼ .001).
Quartiles of Serum Uric Acid Levels
Male patients were more likely to have elevated preoper-
ative serum uric acid levels. Patients with higher levels also
tended to be older and to have poorer renal function, a higher
body mass index, impaired left ventricular systolic function,
and a higher EuroSCORE (Table 3). The excess risk associ-
ated with an elevated uric acid was particularly evident in pa-
tients in the upper quartile (Table 1 and Figure 1). The HR
associated with a serum uric acid level in this quartile
(410 mmol/L) was 2.18 (95% CI, 1.53–3.11; P< .001
vs all other quartiles combined).
Further regressionmodelswere developed, similar to those
described above but replacing uric acid as a continuous vari-
ablewith uric acid in the upper quartile (vs all other quartiles).
In the first of these, including all variables in Table 2, the up-
per quartile of preoperative uric acid levels remained inde-
pendently predictive (HR 1.56; 95% CI, 1.08–2.26; P ¼
.02). In a model with the EuroSCORE alone, the hazard asso-
ciated with a uric acid level in the upper quartile was 1.76
(95% CI, 1.23–2.52; P ¼ .002).
Hyperuricemia
Hyperuricemia closely approximates the upper quartile of
uric acid in the current cohort and is also associated with
a worse survival (Table 1). In a regression model that in-
cluded hyperuricemia and EuroSCORE only, the former
was an independent predictor of death (HR 1.48; 95% CI,Cardiovascular Surgery c Volume 138, Number 1 201
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All-cause mortality
Characteristic
All patients
(n ¼ 1140) Alive (n ¼ 1014) Died (n ¼ 126)
Hazard ratio
(95% CI) P value
Age, y 66 (59–71) 65 (58–71) 70 (65–75) 2.18 (1.73–2.74)* <.001
Risk factors and medical history
Male 893 (78%) 795 (78%) 98 (78%) 0.94 (0.62–1.43) .776
Current smoker 112 (10%) 98 (10%) 14 (11%) 1.14 (0.66–1.99) .641
Diabetes 126 (11%) 107 (11%) 19 (15%) 1.42 (0.87–2.31) .162
Hypertension 504 (44%) 446 (44%) 58 (46%) 1.00 (0.70–1.41) .978
Body mass index 27.8  3.9 27.9  3.9 27.2  3.6 0.79 (0.63–1.00) .053
Prior CABG 26 (2%) 20 (2%) 6 (5%) 2.21 (0.97–5.01) .059
Previous MI (>7 d) 484 (42%) 424 (42%) 60 (48%) 1.14 (0.80–1.61) .479
LVEF<50% 394 (35%) 333 (3%) 61 (48%) 1.78 (1.25–2.53) .001
NYHA functional class III or IV 757 (66%) 678 (67%) 79 (63%) 0.89 (0.62–1.28) .543
Additional major cardiac procedure 117 (10%) 91 (9%) 26 (21%) 2.64 (1.71–4.06) <.001
Bypass time (15 min) 79 (62–97) 79 (61–96) 86 (67–113) 1.14 (1.08–1.19) <.001
Crossclamp time (15 min) 44 (33–54) 44 (33–54) 45 (35–63) 1.15 (1.07–1.24) <.001
Off-pump surgery 102 (9%) 94 (9%) 8 (6%) 0.76 (0.37–1.55) .442
EuroSCORE 4 (2–6) 3 (2–5) 6 (4–8) 1.34 (1.26–1.43) <.001
Renal function
Creatinine (mg/dL) 1.21  0.48 1.18  0.39 1.41  0.90 1.49 (1.28–1.75)y <.001
Estimated GFR (mL/min/1.73 m2) 64.8  14.7 65.6  14.2 58.1  17.1 0.73 (0.65–0.81)z <.001
Uric acid (mmol/L) 357  92 353  86 390  131 1.48 (1.25–1.74)x <.001
Quartile of uric acid level
Quartile 1 278 (24%) 248 (25%) 30 (24%) 1 –
Quartile 2 281 (25%) 257 (25%) 24 (19%) 0.80 (0.47–1.37) .42
Quartile 3 295 (26%) 274 (27%) 21 (17%) 0.67 (0.38–1.17) .16
Quartile 4 286 (25%) 235 (23%) 51 (41%) 1.79 (1.14–2.81) .01
Hyperuricemiak 284 (25%) 237 (31%) 47 (37%) 1.92 (1.33–2.75) <.001
CABG, Coronary artery bypass grafting; MI, myocardial infarction; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association, GFR, glomerular filtration rate;
CI, confidence interval; EuroSCORE, European System for Cardiac Operative Risk Evaluation. *HR per decade. yHR per mg/dL. zHR per 10 mL/min/1.73 m2. xHR per 100 mmol/L.
kSee text for details.1.02–2.13; P ¼ .04). Similarly, in a model including all the
variables in Table 2, but with hyperuricemia replacing uric
acid as a continuous variable, there was a trend toward hy-
peruricemia independently predicting mortality (HR 1.35;
95% CI, 0.93–1.96; P ¼ .11).
Secondary Analyses
Cardiovascular mortality. Preoperative uric acid level
was a univariable predictor of cardiovascular death (HR
1.51 per 100 mmol/L; 95% CI, 1.27–1.79; P< .001). In
a multiple Cox regression model including all variables, se-
lected as described above, uric acid was a predictor of car-
diovascular death (HR 1.27 per 100 mmol/L; 95% CI,
1.07–1.51; P ¼ .008). In a model with only EuroSCORE
and uric acid, the HR was 1.33 per 100 mmol/L (95% CI,
1.13–1.57; P¼ .001). Patients with uric acid levels in the up-
per quartile had an HR of 1.89 for cardiovascular death
(95% CI, 1.29–2.76; P ¼ .001) even after correction for
their EuroSCORE.
Patients undergoing isolated CABG. Of 1023 patients
undergoing isolated CABG, 100 (10%) died during fol-202 The Journal of Thoracic and Cardiovascular Sulow-up. Preoperative uric acid levels remained univariable
predictors of all-cause mortality in this subgroup (HR 1.30
per 100 mmol/L; 95% CI, 1.06–1.59; P ¼ .01). They re-
mained independent predictors after correction for Euro-
SCORE (HR 1.21 per 100 mmol/L; 95% CI, 1.00–1.46;
P ¼ .049). However, although a similar trend was observed
(P ¼ .18), they failed to achieve statistical significance in
a model including all variables (except the EuroSCORE
and crossclamp time), selected as described above.
Mortality at 30 days. Twenty-three patients (2%) died
within 30 days of surgery. Preoperative uric acid levels
TABLE 2. Multivariable predictors of mortality
Characteristic Hazard ratio 95% CI P value
Age (per 10 y) 1.93 1.53–2.43 <.001
Creatinine (per mg/dL) 1.42 1.18–1.72 <.001
Bypass time (per 15 min) 1.10 1.04–1.16 <.001
Left ventricular ejection
fraction<50%
1.67 1.17–2.39 .005
Uric acid (per 100 mmol/L) 1.25 1.06–1.47 .009
CI, Confidence interval.rgery c July 2009
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Characteristic
Quartile 1
70–299 mmol/L
n ¼ 278
Quartile 2
300–349 mmol/L
n ¼ 281
Quartile 3
350–409 mmol/L
n ¼ 295
Quartile 4
410–830 mmol/L
n ¼ 286 P value
Age (y) 64 (58–71) 65 (57–70) 66 (59–70) 68 (62–74) <.001
Male 182 (65%) 225 (80%) 255 (86%) 231 (81%) <.001
Creatinine (mg/dL) 1.12  0.57 1.14  0.39 1.24  0.56 1.32  0.31 <.001
eGFR (mL/min/1.73 m2) 68.9  15.2 68.1  12.9 64.6  13.7 57.8  14.4 <.001
Body mass index 26.7  3.8 27.4  3.6 28.3  3.7 28.6  4.3 <.001
Hypertension 125 (45%) 113 (40%) 132 (45%) 134 (47%) .43
Diabetes mellitus 43 (15%) 27 (10%) 19 (6%) 37 (13%) .20
Smoker 32 (12%) 27 (10%) 32 (11%) 21 (7%) .16
Previous myocardial infarction 118 (42%) 116 (41%) 122 (41%) 128 (45%) .59
LVEF<50% 82 (29%) 76 (27%) 105 (36%) 131 (46%) <.001
NYHA functional class III or IV 196 (71%) 178 (63%) 188 (64%) 195 (68%) .61
EuroSCORE 4 (2–5) 3 (2–5) 3 (2–5) 4 (2–7) .004
eGFR, Estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.were predictors of 30-day mortality (odds ratio 1.74 per 100
mmol/L; 95% CI, 1.23–2.47; P ¼ .002). In a multivariable
model that also included the EuroSCORE, the odds ratio
for death at 30 days was 1.41 greater for every 100 mmol/
L increase in uric acid levels (95% CI, 1.00–2.00; P ¼
.05). The small number of events limits the ability to under-
take further modeling.
Late mortality. Uric acid levels remained predictive of late
mortality (defined as deaths that occurred more than 30 days
after surgery, n ¼ 103): HR 1.41 per 100 mmol/L; 95% CI,
1.17–1.71; P<.001. This remained the case in a model that
included the EuroSCORE (HR 1.29 per 100 mmol/L; 95%
CI, 1.08–1.55; P ¼ .006) and in a further model including
all variables (except the EuroSCORE and crossclamp
time), selected as described above (HR 1.24 per 100 mmol/
L; 95% CI, 1.03–1.50; P ¼ .03).
DISCUSSION
The current data demonstrate that elevated levels of serum
uric acid are common among patients undergoing CABGThe Journal of Thoracic and Cand are strongly and independently predictive of increased
mortality in this setting. The excess hazard of death was con-
centrated among patients with uric acid levels in the upper
quartile whose risk of death during a median follow-up of
4.5 years was increased by 76%, even after adjustment for
their preoperative EuroSCORE.
Previous Studies
No previous studies have addressed the utility of serum
uric acid in predicting the outcome of CABG. Several large
epidemiologic studies have, however, demonstrated a strong
relationship between uric acid and cardiovascular out-
come.3,9,10 Although elevated levels of uric acid are associ-
ated with cardiovascular risk factors, including components
of the metabolic syndrome such as obesity, diabetes melli-
tus, and hypertension, the majority of studies have demon-
strated that their predictive value is independent of
these.3,24 In high-risk patients, or patients with preexisting
cardiovascular disease, high levels of uric acid are associated
with a particularly poor outcome. As observed in the currentP
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tients with the highest levels.3,9
Potential Mechanisms
The adverse outcome associated with elevated levels of
uric acid may be multifactorial. Some of the prognostic util-
ity may relate to its ability to integrate the effects of several
other factors that determine a worse outcome. Certainly,
conditions such as diabetes, hypertension, and renal dys-
function, all of which predispose to hyperuricemia, are
well known to confer an adverse prognosis. However, the
prognostic utility of uric acid is independent of these factors,
suggesting that other mechanisms may be involved.
Data from the Atherosclerosis Risk in Communities study
suggest that levels of uric acid are related to carotid intima–
media thickness, a direct measure of atherosclerotic bur-
den.25 Elevated uric acid levels may also induce platelet lysis
and increase adhesiveness.6,7 In addition, recent data have
shown that uric acid levels are strongly and independently
associated with elevations of inflammatory markers, includ-
ing the leukocyte and neutrophil count, C-reactive protein,
and proinflammatory cytokines.8 Several of these have, in
turn, been associated with a poorer outcome in patients un-
dergoing CABG.
Uric acid is formed from xanthine in a reaction catalyzed
by xanthine oxidoreductase.26 This enzyme exists in 2 inter-
convertible forms: xanthine oxidase and xanthine dehydro-
genase.27 Xanthine oxidoreductase has many complex
actions, including the production of reactive oxygen spe-
cies.27,28 Thus, it plays an important role in ischemia-reper-
fusion injury, including that after cardiac surgery. It is
conceivable that high levels of uric acid identify patients
with high xanthine oxidoreductase activity and who are,
therefore, at particular risk of perioperative reperfusion in-
jury. Indeed, allopurinol, a competitive inhibitor of xanthine
oxidase that is commonly used to treat hyperuricemia, may
have a role in perioperative myocardial protection.28-30
Study Strengths and Limitations
This is a single-center study with the inherent limitations.
It does, however, assess the outcome of a large cohort of
consecutive patients, allowing the use of all-cause mortality
as the objective primary end point. The absence of data
regarding other, nonfatal, outcomes is a limitation, as is
the reliance on a single measurement of uric acid.
The incidence of diabetes mellitus in the study cohort is
lower than might be expected. This diagnosis was based
on a clinical history of the condition and may, therefore,
be an underestimate. The lack of data regarding a clinical
history of gout and drug therapy are further limitations. Un-
fortunately, these data were not collected prospectively, and
the medical records of the majority of patients who have died
have been destroyed. It is not possible, therefore, to correct204 The Journal of Thoracic and Cardiovascular Surfor the effects of medication, and in particular treatment with
diuretics.
Despite these limitations, the current data demonstrate for
the first time a strong and independent relationship between
preoperative levels of uric acid, particularly those in the up-
per quartile, and mortality after CABG. Further work is re-
quired to corroborate these findings and confirm whether
incorporation of this easily measured biomarker can improve
the prognostic accuracy of existing or novel methods of pre-
operative risk stratification. Likewise, it remains uncertain
whether elevated levels of uric acid are mediators or merely
markers of increased mortality. More research, therefore, is
required before treatment of uric acid can be recommended
specifically to reduce cardiovascular risk in this setting.
CONCLUSIONS
The current study confirms that elevated uric acid levels
are a marker of increased risk after cardiac surgery.
Although no causal mechanism can be inferred, high levels
may be associated with an increased risk of reperfusion in-
jury and a variety of factors that determine both early and
long-term outcome, such as inflammatory cell and platelet
activation, increased atherosclerotic burden, and increased
prevalence of major cardiovascular risk factors.
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